BIOMAT Database Logo BIOMAT Database Logo

The combination of quercetin and cytosine arabinoside synergistically inhibits leukemic cell growth. 1992

L Teofili, and L Pierelli, and M S Iovino, and G Leone, and G Scambia, and R De Vincenzo, and P Benedetti-Panici, and G Menichella, and E Macrì, and M Piantelli
Istituti di Semeiotica Medica, Università Cattolica del Sacro Cuore, Roma, Italy.

It has been demonstrated that quercetin (3,3',4',5,7-pentahydroxyflavone) inhibits the growth of several cancer cell lines and that the antiproliferative activity of this substance is probably mediated through a binding interaction with type II estrogen binding sites (type II EBS). The effect of quercetin and cytosine arabinoside (Ara-C) alone or in combination, was tested on HL-60 cell growth. Quercetin significantly synergized the inhibitory activity of Ara-C on HL-60 cell growth while rutin, the 3-rhamnosylglucoside of quercetin, neither competed with [3H]estradiol for type II EBS nor was effective alone or in combination with Ara-C. Based on these results, we studied by a clonogenic assay the effect of quercetin and Ara-C alone and in combination on colony formation by human leukemic cells (CFU-L). In all cases both drugs exhibited a dose-related inhibition of CFU-L in a range of concentrations between 10 nM and 10 microM and 0.01 nM and 10 microM for quercetin and Ara-C, respectively. The combination of the two drugs resulted in a synergistic inhibitory activity on CFU-L. Considering that plasma concentrations of quercetin effective in vitro were obtained in vivo without any apparent side effects, we conclude that this report represents further experimental evidence that quercetin could be used in the treatment of acute leukemias.

UI MeSH Term Description Entries
D007951 Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites. Granulocytic Leukemia,Leukemia, Granulocytic,Leukemia, Myelocytic,Leukemia, Myelogenous,Myelocytic Leukemia,Myelogenous Leukemia,Myeloid Leukemia,Leukemia, Monocytic, Chronic,Monocytic Leukemia, Chronic,Chronic Monocytic Leukemia,Chronic Monocytic Leukemias,Granulocytic Leukemias,Leukemia, Chronic Monocytic,Leukemias, Chronic Monocytic,Leukemias, Granulocytic,Leukemias, Myelocytic,Leukemias, Myelogenous,Leukemias, Myeloid,Monocytic Leukemias, Chronic,Myelocytic Leukemias,Myelogenous Leukemias,Myeloid Leukemias
D011794 Quercetin A flavonol widely distributed in plants. It is an antioxidant, like many other phenolic heterocyclic compounds. Glycosylated forms include RUTIN and quercetrin. 3,3',4',5,7-Pentahydroxyflavone,Dikvertin
D011960 Receptors, Estrogen Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important. Estrogen Receptor,Estrogen Receptors,Estrogen Nuclear Receptor,Estrogen Receptor Type I,Estrogen Receptor Type II,Estrogen Receptors Type I,Estrogen Receptors Type II,Receptor, Estrogen Nuclear,Receptors, Estrogen, Type I,Receptors, Estrogen, Type II,Nuclear Receptor, Estrogen,Receptor, Estrogen
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D014410 Tumor Stem Cell Assay A cytologic technique for measuring the functional capacity of tumor stem cells by assaying their activity. It is used primarily for the in vitro testing of antineoplastic agents. Clonogenic Cell Assay, Tumor,Colony-Forming Units Assay, Tumor,Neoplasm Stem Cell Assay,Stem Cell Assay, Tumor,Colony Forming Units Assay, Tumor

Related Publications

L Teofili, and L Pierelli, and M S Iovino, and G Leone, and G Scambia, and R De Vincenzo, and P Benedetti-Panici, and G Menichella, and E Macrì, and M Piantelli
Effect of stem cell factor on leukemic progenitor cell growth and sensitivity to cytosine-arabinoside.
January 1996, Leukemia research,
L Teofili, and L Pierelli, and M S Iovino, and G Leone, and G Scambia, and R De Vincenzo, and P Benedetti-Panici, and G Menichella, and E Macrì, and M Piantelli
Effect of cytosine arabinoside on leukemic blast cell colonies.
June 1986, American journal of hematology,
L Teofili, and L Pierelli, and M S Iovino, and G Leone, and G Scambia, and R De Vincenzo, and P Benedetti-Panici, and G Menichella, and E Macrì, and M Piantelli
[Cytosine arabinoside in the treatment of leukemic meningitis].
January 1972, Haematologica,
L Teofili, and L Pierelli, and M S Iovino, and G Leone, and G Scambia, and R De Vincenzo, and P Benedetti-Panici, and G Menichella, and E Macrì, and M Piantelli
Accumulation of leukemic cell DNA strand breaks with adriamycin and cytosine arabinoside.
January 1983, Leukemia research,
L Teofili, and L Pierelli, and M S Iovino, and G Leone, and G Scambia, and R De Vincenzo, and P Benedetti-Panici, and G Menichella, and E Macrì, and M Piantelli
Combination simvastatin and metformin synergistically inhibits endometrial cancer cell growth.
August 2019, Gynecologic oncology,
L Teofili, and L Pierelli, and M S Iovino, and G Leone, and G Scambia, and R De Vincenzo, and P Benedetti-Panici, and G Menichella, and E Macrì, and M Piantelli
[Clinical use of cytosine arabinoside in childhood. II. Cytosine arabinoside in the prevention and therapy of leukemic meningosis].
September 1975, Minerva pediatrica,
L Teofili, and L Pierelli, and M S Iovino, and G Leone, and G Scambia, and R De Vincenzo, and P Benedetti-Panici, and G Menichella, and E Macrì, and M Piantelli
Preliminary results of a trial on acute myeloid leukemia comparing the effect of cytosine arabinoside, the combination of cytosine arabinoside and thioguanine and the combination of cytosine arabinoside and daunorubicine.
January 1973, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
L Teofili, and L Pierelli, and M S Iovino, and G Leone, and G Scambia, and R De Vincenzo, and P Benedetti-Panici, and G Menichella, and E Macrì, and M Piantelli
Growth factors influence the sensitivity of leukemic stem cells to cytosine arabinoside in culture.
April 1989, Blood,
L Teofili, and L Pierelli, and M S Iovino, and G Leone, and G Scambia, and R De Vincenzo, and P Benedetti-Panici, and G Menichella, and E Macrì, and M Piantelli
Cytosine arabinoside in experimental combination therapy.
June 1985, Seminars in oncology,
L Teofili, and L Pierelli, and M S Iovino, and G Leone, and G Scambia, and R De Vincenzo, and P Benedetti-Panici, and G Menichella, and E Macrì, and M Piantelli
Combination chemotherapy: the antagonism of methotrexate and cytosine arabinoside.
March 1973, European journal of cancer,
Copied contents to your clipboard!